PROGRAM CHAIR
Edward B. Garon, MD, MS, FASCO
Professor, David Geffen School of Medicine at UCLA
Los Angeles, CA
PROGRAM OVERVIEW
This podcast series is designed to answer your questions about selecting and using a first-line immune checkpoint inhibitor-based regimen for your patients with metastatic non-small cell lung cancer that does not harbor a driver gene alteration. During the first podcast, Dr Edward Garon reviews and shares perspectives on current evidence-based practice guidelines for this setting, as well as relevant supporting phase 3 clinical trial data. Additionally, he shares how he approaches clinical areas of uncertainty. In the second podcast, the conversation shifts to best practices for helping your patients get through ICI-based therapy as safely and efficaciously as possible.
TARGET AUDIENCE
This activity is designed to meet the educational needs of global medical oncologists, oncology nurses, pharmacists, nurse practitioners and other members of the multidisciplinary team in the community setting to maintain an up-to-date understanding of the latest data on immune checkpoint inhibitor regimens in the management of NSCLC.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Evaluate the efficacy and safety clinical trials data from immune checkpoint inhibitor (ICI) and chemotherapy combination regimens in the first-line management of patients with advanced non-small cell lung cancer (NSCLC)
- Apply clinical practice guidelines to patient care setting for individuals with metastatic NSCLC without actionable mutations
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in this enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Edward B. Garon, MD, MS, FASCO | Dr. Garon discloses that he is a consultant and/or advisor for Abbvie, Arcus, AstraZeneca, Atreca, BridgeBio, Bristol Myers Squibb, EMD Serono, Eli Lilly, Gilead, GlaxoSmithKline, Hookipa, LianBio, Merck, Merus, Novartis, Nuvalent, Personalis, Regeneron, Sanofi, Seagan, Sensei, Sumitomo, Summit, Synthekine, Xilio, and Zymeworks. He has conducted research for ABL-Bio, Arrivent, AstraZeneca, Bristol Myers Squibb, Daiichi Sanko, Eli Lilly, EMD Serono, Genentech, Gilead, Iovance Biotherapeutics, Merck, Mirati Therapeutics, Novartis, Prelude, Regeneron, and Synthekine. He has conducted independent medical education for Daiichi-Sankyo, and Ipsen. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Arpan Patel, MD, has nothing to disclose.
- Kim L Farina, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Jacquelyn Sandfort, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
RELEASED DATE: June 14, 2024
EXPIRATION DATE: June 14, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIR
Edward B. Garon, MD, MS, FASCO
Professor, David Geffen School of Medicine at UCLA
Los Angeles, CA
PROGRAM OVERVIEW
This podcast series is designed to answer your questions about selecting and using a first-line immune checkpoint inhibitor-based regimen for your patients with metastatic non-small cell lung cancer that does not harbor a driver gene alteration. During the first podcast, Dr Edward Garon reviews and shares perspectives on current evidence-based practice guidelines for this setting, as well as relevant supporting phase 3 clinical trial data. Additionally, he shares how he approaches clinical areas of uncertainty. In the second podcast, the conversation shifts to best practices for helping your patients get through ICI-based therapy as safely and efficaciously as possible.
TARGET AUDIENCE
This activity is designed to meet the educational needs of global medical oncologists, oncology nurses, pharmacists, nurse practitioners and other members of the multidisciplinary team in the community setting to maintain an up-to-date understanding of the latest data on immune checkpoint inhibitor regimens in the management of NSCLC.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Apply clinical practice guidelines to patient care setting for individuals with metastatic NSCLC without actionable mutations
- Discuss the timely recognition and management of immune related adverse events (irAEs) in patients with advanced NSCLC treated with immunotherapy
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in this enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Edward B. Garon, MD, MS, FASCO | Dr. Garon discloses that he is a consultant and/or advisor for Abbvie, Arcus, AstraZeneca, Atreca, BridgeBio, Bristol Myers Squibb, EMD Serono, Eli Lilly, Gilead, GlaxoSmithKline, Hookipa, LianBio, Merck, Merus, Novartis, Nuvalent, Personalis, Regeneron, Sanofi, Seagan, Sensei, Sumitomo, Summit, Synthekine, Xilio, and Zymeworks. He has conducted research for ABL-Bio, Arrivent, AstraZeneca, Bristol Myers Squibb, Daiichi Sanko, Eli Lilly, EMD Serono, Genentech, Gilead, Iovance Biotherapeutics, Merck, Mirati Therapeutics, Novartis, Prelude, Regeneron, and Synthekine. He has conducted independent medical education for Daiichi-Sankyo, and Ipsen. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Arpan Patel, MD, has nothing to disclose.
- Kim L Farina, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Jacquelyn Sandfort, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
RELEASED DATE: June 21, 2024
EXPIRATION DATE: June 21, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
